U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Paraganglioma

MedGen UID:
1682526
•Concept ID:
C4764216
•
Neoplastic Process

Definition

A paraganglioma that does not respond to treatment. [from NCI]

Professional guidelines

PubMed

Current management of carotid body tumors.
Ozawa H
Auris Nasus Larynx 2024 Jun;51(3):501-506. Epub 2024 Mar 23 doi: 10.1016/j.anl.2024.01.007. PMID: 38522353
The diagnosis and management of pheochromocytoma and paraganglioma during pregnancy.
Clifton-Bligh RJ
Rev Endocr Metab Disord 2023 Feb;24(1):49-56. Epub 2023 Jan 13 doi: 10.1007/s11154-022-09773-2. PMID: 36637675Free PMC Article
Recent advances in the management of pheochromocytoma and paraganglioma.
Tanabe A, Naruse M
Hypertens Res 2020 Nov;43(11):1141-1151. Epub 2020 Aug 11 doi: 10.1038/s41440-020-0531-0. PMID: 32778780

Recent clinical studies

Therapy

Prognostic factors for refractory pheochromocytoma and paraganglioma after (131)I-metaiodobenzylguanidine therapy.
Hiromasa T, Wakabayashi H, Kayano D, Inaki A, Watanabe S, Mori H, Akatani N, Yamase T, Kunita Y, Saito S, Kinuya S
Ann Nucl Med 2022 Jan;36(1):61-69. Epub 2021 Oct 13 doi: 10.1007/s12149-021-01685-6. PMID: 34647244
Radiopharmaceuticals for Neuroendocrine Tumors.
Chin RI, Wu FS, Menda Y, Kim H
Semin Radiat Oncol 2021 Jan;31(1):60-70. doi: 10.1016/j.semradonc.2020.07.007. PMID: 33246637
A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma.
Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, Jinguji M, Shiga T, Kinuya S
Sci Rep 2019 May 20;9(1):7625. doi: 10.1038/s41598-019-43880-6. PMID: 31110198Free PMC Article
The evolving landscape of neuroendocrine tumors.
Bergsland EK
Semin Oncol 2013 Feb;40(1):4-22. doi: 10.1053/j.seminoncol.2012.11.013. PMID: 23391109
131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.
Grünwald F, Ezziddin S
Semin Nucl Med 2010 Mar;40(2):153-63. doi: 10.1053/j.semnuclmed.2009.11.004. PMID: 20113683

Prognosis

Current management of carotid body tumors.
Ozawa H
Auris Nasus Larynx 2024 Jun;51(3):501-506. Epub 2024 Mar 23 doi: 10.1016/j.anl.2024.01.007. PMID: 38522353
Prognostic factors for refractory pheochromocytoma and paraganglioma after (131)I-metaiodobenzylguanidine therapy.
Hiromasa T, Wakabayashi H, Kayano D, Inaki A, Watanabe S, Mori H, Akatani N, Yamase T, Kunita Y, Saito S, Kinuya S
Ann Nucl Med 2022 Jan;36(1):61-69. Epub 2021 Oct 13 doi: 10.1007/s12149-021-01685-6. PMID: 34647244
Radiopharmaceuticals for Neuroendocrine Tumors.
Chin RI, Wu FS, Menda Y, Kim H
Semin Radiat Oncol 2021 Jan;31(1):60-70. doi: 10.1016/j.semradonc.2020.07.007. PMID: 33246637
A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma.
Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, Jinguji M, Shiga T, Kinuya S
Sci Rep 2019 May 20;9(1):7625. doi: 10.1038/s41598-019-43880-6. PMID: 31110198Free PMC Article
Metastatic pheochromocytoma and paraganglioma.
Angelousi A, Kassi E, Zografos G, Kaltsas G
Eur J Clin Invest 2015 Sep;45(9):986-97. doi: 10.1111/eci.12495. PMID: 26183460

Clinical prediction guides

Current management of carotid body tumors.
Ozawa H
Auris Nasus Larynx 2024 Jun;51(3):501-506. Epub 2024 Mar 23 doi: 10.1016/j.anl.2024.01.007. PMID: 38522353
Prognostic factors for refractory pheochromocytoma and paraganglioma after (131)I-metaiodobenzylguanidine therapy.
Hiromasa T, Wakabayashi H, Kayano D, Inaki A, Watanabe S, Mori H, Akatani N, Yamase T, Kunita Y, Saito S, Kinuya S
Ann Nucl Med 2022 Jan;36(1):61-69. Epub 2021 Oct 13 doi: 10.1007/s12149-021-01685-6. PMID: 34647244
Radiopharmaceuticals for Neuroendocrine Tumors.
Chin RI, Wu FS, Menda Y, Kim H
Semin Radiat Oncol 2021 Jan;31(1):60-70. doi: 10.1016/j.semradonc.2020.07.007. PMID: 33246637
Recent advances in the management of pheochromocytoma and paraganglioma.
Tanabe A, Naruse M
Hypertens Res 2020 Nov;43(11):1141-1151. Epub 2020 Aug 11 doi: 10.1038/s41440-020-0531-0. PMID: 32778780
Metastatic pheochromocytoma and paraganglioma.
Angelousi A, Kassi E, Zografos G, Kaltsas G
Eur J Clin Invest 2015 Sep;45(9):986-97. doi: 10.1111/eci.12495. PMID: 26183460

Recent systematic reviews

Extracorporeal life support for phaeochromocytoma-induced cardiogenic shock: a systematic review.
Matteucci M, Kowalewski M, Fina D, Jiritano F, Meani P, Raffa GM, Aldobayyan I, Beghi C, Maessen J, Lorusso R
Perfusion 2020 May;35(1_suppl):20-28. doi: 10.1177/0267659120908413. PMID: 32397890

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...